PRADO: Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose
Study Details
Study Description
Brief Summary
Primary objective:
To determine the effect of Rimonabant 20mg on the co-primary endpoint including Fasting Plasma Glucose (FPG), HDL-Cholesterol (HDL-C) and triglyceride (TG) levels over a period of 12 months when prescribed with a mild hypocaloric diet in abdominally obese patients with impaired fasting blood glucose and with or without associated comorbidities.
Main Secondary objectives:
To determine the effect of 12 months Rimonabant treatment versus placebo on changes in waist circumference (WC), body weight, glycemic parameters and lipid parameters.
To assess the safety of 12 months Rimonabant treatment versus placebo in these patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: 1 Administration of one tablet containing 20 mg of Rimonabant |
Drug: Rimonabant
Once daily in the morning
|
| Placebo Comparator: 2 Administration of one Rimonabant placebo tablet. |
Drug: Placebo
Once daily in the morning
|
Outcome Measures
Primary Outcome Measures
- Mean change in the co-primary endpoint : FPG, HDL-C and triglyceride levels. [From baseline to end of treatment]
Secondary Outcome Measures
- Waist circumference and body weight [At each visit]
- Glycemic parameters (FPG, fasting insulinemia, HbA1c), lipid parameters (Total Cholesterol, HDL-C, LDL-C, triglyceride levels), inflammatory parameter (Hs-CRP), [All these laboratory parameters will be measured prior to baseline, month 3, month 6 and month 12.]
- Quality of life (IWQOL questionnaire completion) [At baseline, month 3, month 6, month 9 and month 12]
- Incidence of adverse events in each group, including neuro-psychiatric adverse events [From the signature of the ICF to the end of the study]
- Standard laboratory assessments [Prior to baseline and month 12]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
BMI ≥ 30Kg/m², or > 27kg/m² if associated with risk factor(s) such as dyslipidemia, and < 40kg/m²,
-
Waist Circumference > 88 cm in women; > 102 cm in men,
-
Confirmed (by at least 2 measurements) impaired Fasting Plasma Glucose (FPG ≥ 100 mg/dl (5.6 mmol/L) and < 126 mg/dl (7.0 mmol/L) in non diabetic patients,
-
LDL cholesterol up to 155 mg/dl (4.00 mmol/L) including patients on a stable dose of statin therapy for at least 8 weeks prior to screening,
-
Current treatment with statins and/or ezetimibe and/or antihypertensive therapy must be at fixed and stable dose for at least 8 weeks prior to screening visit,
-
Patients, who are willing and in the opinion of the Investigator safely assumed to remain on stable and fixed doses of antihypertensive, and/or statins and/or ezetimibe without adding additional medications or changing current treatment for the duration of the trial.
Exclusion Criteria:
-
Pregnant or breast-feeding women, or women planning to become pregnant or breastfeed (excluded by pregnancy test),
-
Absence of medically approved contraceptive methods for female of childbearing potential,
-
History of very low-calorie diet within 3 months prior to screening visit (lower than 1200 Kcal/day),
-
Weight change > 5 kg within 3 months prior to screening visit,
-
History of surgical procedures for weight loss (e.g., stomach stapling, bypass),
-
History of bulimia or anorexia nervosa as per DSM-IV criteria,
-
Presence of any clinically significant endocrine disease according to the investigator, in particular known abnormal TSH and free T4 blood level (Patients treated with thyroid replacement therapy must be on fixed and stable dose for at least 3 months prior to screening and must be in euthyroïd status),
-
Established type 1 or 2 diabetes treated, or with at least 2 measures of fasting blood glucose ≥ 126 mg/dl /L,
-
Triglyceride level > 400 mg/dL (4.52 mmol),
-
Systolic blood pressure > 160 mm Hg or diastolic blood pressure >100 mmHg at screening visit,
-
Known severe renal dysfunction (creatinine clearance < 30 ml/min) or nephrotic syndrome or urinalysis (performed at screening by dipstick) showing 2+ or more protein,
-
Known severe hepatic impairment or AST and/or ALT > 3 times the upper limit of normal at screening,
-
Presence of any condition (medical, including clinically significant abnormal laboratory tests, psychological, social or geographical) actual or anticipated that the investigator feels would compromise the patient's safety or limit his/her successful participation to the study. In particular :
-
Cardiac abnormalities: cardiac failure status NYHA III or IV, relevant acute abnormal finding seen on ECG at screening or within 6 months before screening,
-
Any current malignancy or any cancer within the past five years (except adequately treated basal cell skin cancer or cervix carcinoma in situ),
-
Significant haematology abnormalities (haemoglobin < 100 g/L and/or neutrophils < 1.5 G/L and/or platelets < 100 G/L),
-
Acute psychiatric disorders or mental condition which could interfere with the patient's compliance or safe participation in the study,
-
Patient treated for epilepsy,
-
Ongoing major depressive illness,
-
Uncontrolled psychiatric illness,
-
History of alcohol or other substance abuse,
-
Hypersensitivity /intolerance to the active substance or to any of the excipients such as lactose,
-
Administration of any investigational treatment (drug or device) within 30 days prior to screening,
-
Previous participation in a Rimonabant study or previous administration of Rimonabant,
-
Administration of any of the following within 3 months prior to screening visit:
-
Anti obesity drugs (eg, sibutramine, orlistat),
-
Other drugs for weight reduction (phentermine, amphetamines),
-
Herbal preparations for weight reduction,
-
Nicotinic acid, fibrates or bile acid sequestrants ,
-
Prolonged use (more than one week) of systemic corticosteroids, neuroleptics.
-
Omega-3 fatty acid approved medication
- Ongoing antidepressive treatment(including bupropion)
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Sanofi-Aventis Administrative Office | Vienna | Austria | ||
| 2 | Sanofi-Aventis Administrative Office | Diegem | Belgium | ||
| 3 | Sanofi-Aventis Administrative Office | Sao Paulo | Brazil | ||
| 4 | Sanofi-Aventis Administrative Office | Sofia | Bulgaria | ||
| 5 | Sanofi-Aventis Administrative Office | Laval | Canada | ||
| 6 | Sanofi-Aventis Administrative Office | Praha | Czech Republic | ||
| 7 | Sanofi-Aventis Administrative Office | Horsholm | Denmark | ||
| 8 | Sanofi-Aventis Administrative Office | Cairo | Egypt | ||
| 9 | Sanofi-Aventis Administrative Office | Helsinki | Finland | ||
| 10 | Sanofi-Aventis Administrative Office | Paris | France | ||
| 11 | Sanofi-Aventis Administrative Office | Kallithea | Greece | ||
| 12 | Sanofi-Aventis Administrative Office | Budapest | Hungary | ||
| 13 | Sanofi-Aventis Administrative Office | Dublin | Ireland | ||
| 14 | Sanofi-Aventis Administrative Office | Natanya | Israel | ||
| 15 | Sanofi-Aventis Administrative Office | Milan | Italy | ||
| 16 | Sanofi-Aventis Administrative Office | Vilnius | Lithuania | ||
| 17 | Sanofi-Aventis Administrative Office | Luxembourg | Luxembourg | ||
| 18 | Sanofi-Aventis Administrative Office | Col. Coyoacan | Mexico | ||
| 19 | Sanofi-Aventis Administrative Office | Gouda | Netherlands | ||
| 20 | Sanofi-Aventis Administrative Office | Lysaker | Norway | ||
| 21 | Sanofi-Aventis Administrative Office | Porto Salvo | Portugal | ||
| 22 | Sanofi-Aventis Administrative Office | Bratislava | Slovakia | ||
| 23 | Sanofi-Aventis Administrative Office | Barcelona | Spain | ||
| 24 | Sanofi-Aventis Administrative Office | Bromma | Sweden | ||
| 25 | Sanofi-Aventis Administrative Office | Geneva | Switzerland | ||
| 26 | Sanofi-Aventis Administrative Office | Istanbul | Turkey | ||
| 27 | Sanofi-Aventis Administrative Office | Guildford Surrey | United Kingdom |
Sponsors and Collaborators
- Sanofi
Investigators
- Study Director: Valérie Pilorget, MD, Sanofi
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RIMON_R_00961
- EUDRACT # : 2006-001711-30